journal
MENU ▼
Read by QxMD icon Read
search

Diabetes Care

journal
https://www.readbyqxmd.com/read/28432087/erratum-diabetic-retinopathy-a-position-statement-by-the-american-diabetes-association-diabetes-care-2017-40-412-418
#1
Sharon D Solomon, Emily Chew, Elia J Duh, Lucia Sobrin, Jennifer K Sun, Brian L VanderBeek, Charles C Wykoff, Thomas W Gardner
No abstract text is available yet for this article.
April 21, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28428368/erratum-efficacy-and-safety-of-lixilan-a-titratable-fixed-ratio-combination-of-insulin-glargine-plus-lixisenatide-in-type-2-diabetes-inadequately-controlled-on-basal-insulin-and-metformin-the-lixilan-l-randomized-trial-diabetes-care-2016-39-1972-1980
#2
Vanita R Aroda, Julio Rosenstock, Carol Wysham, Jeffrey Unger, Diego Bellido, Guillermo González-Gálvez, Akane Takami, Hailing Guo, Elisabeth Niemoeller, Elisabeth Souhami, Richard M Bergenstal
No abstract text is available yet for this article.
April 20, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28420700/diabetes-associated-clinical-spectrum-long-term-prognosis-and-genotype-phenotype-correlations-in-201-adult-patients-with-hepatocyte-nuclear-factor-1-b-hnf1b-molecular-defects
#3
Danièle Dubois-Laforgue, Erika Cornu, Cécile Saint-Martin, Joël Coste, Christine Bellanné-Chantelot, José Timsit
OBJECTIVE: Molecular defects of hepatocyte nuclear factor 1B (HNF1B) are associated with a multiorgan disease, including diabetes (maturity-onset diabetes of the young 5) and kidney abnormalities. The HNF1B-syndrome is related to HNF1B mutations or to a 17q12 deletion spanning 15 genes, including HNF1B. Here, we described HNF1B-related diabetes and associated phenotypes and assessed genotype/phenotype correlations at diagnosis and in the long-term. RESEARCH DESIGN AND METHODS: This multicenter retrospective cohort study included 201 patients, aged 18 or older at follow-up, with HNF1B mutations (n = 101) or deletion (n = 100)...
April 18, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28420699/erratum-alogliptin-a-dipeptidyl-peptidase-4-inhibitor-prevents-the-progression-of-carotid-atherosclerosis-in-patients-with-type-2-diabetes-the-study-of-preventive-effects-of-alogliptin-on-diabetic-atherosclerosis-spead-a-diabetes-care-2016-39-139-148
#4
Tomoya Mita, Naoto Katakami, Hidenori Yoshii, Tomio Onuma, Hideaki Kaneto, Takeshi Osonoi, Toshihiko Shiraiwa, Keisuke Kosugi, Yutaka Umayahara, Tsunehiko Yamamoto, Hiroki Yokoyama, Nobuichi Kuribayashi, Hideaki Jinnouchi, Masahiko Gosho, Iichiro Shimomura, Hirotaka Watada
No abstract text is available yet for this article.
April 18, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28420698/erratum-evaluation-of-efficacy-and-safety-of-the-glucagon-receptor-antagonist-ly2409021-in-patients-with-type-2-diabetes-12-and-24-week-phase-2-studies-diabetes-care-2016-39-1241-1249
#5
Christof M Kazda, Ying Ding, Ronan P Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E Watson, Andrew J Lewin, William H Landschulz, Mark A Deeg, David E Moller, Thomas A Hardy
No abstract text is available yet for this article.
April 18, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28420697/erratum-sitagliptin-attenuates-the-progression-of-carotid-intima-media-thickening-in-insulin-treated-patients-with-type-2-diabetes-the-sitagliptin-preventive-study-of-intima-media-thickness-evaluation-spike-a-randomized-controlled-trial-diabetes-care-2016-39
#6
Tomoya Mita, Naoto Katakami, Toshihiko Shiraiwa, Hidenori Yoshii, Tomio Onuma, Nobuichi Kuribayashi, Takeshi Osonoi, Hideaki Kaneto, Keisuke Kosugi, Yutaka Umayahara, Tsunehiko Yamamoto, Kazunari Matsumoto, Hiroki Yokoyama, Mamiko Tsugawa, Masahiko Gosho, Iichiro Shimomura, Hirotaka Watada
No abstract text is available yet for this article.
April 18, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28420696/erratum-benefits-of-lixilan-a-titratable-fixed-ratio-combination-of-insulin-glargine-plus-lixisenatide-versus-insulin-glargine-and-lixisenatide-monocomponents-in-type-2-diabetes-inadequately-controlled-on-oral-agents-the-lixilan-o-randomized-trial-diabetes
#7
Julio Rosenstock, Ronnie Aronson, George Grunberger, Markolf Hanefeld, PierMarco Piatti, Pierre Serusclat, Xi Cheng, Tianyue Zhou, Elisabeth Niemoeller, Elisabeth Souhami, Melanie Davies
No abstract text is available yet for this article.
April 18, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28416475/use-of-canagliflozin-in-kidney-transplant-recipients-for-the-treatment-of-type-2-diabetes-a-case-series
#8
LETTER
Harindra Rajasekeran, S Joseph Kim, Carl J Cardella, Jeffrey Schiff, Mark Cattral, David Z I Cherney, Sunita K S Singh
No abstract text is available yet for this article.
April 17, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28404659/early-glycemic-control-and-magnitude-of-hba1c-reduction-predict-cardiovascular-events-and-mortality-population-based-cohort-study-of-24-752-metformin-initiators
#9
Elisabeth Svensson, Lisbeth M Baggesen, Søren P Johnsen, Lars Pedersen, Helene Nørrelund, Esben S Buhl, Christiane L Haase, Reimar W Thomsen
OBJECTIVE: We investigated the association of early achieved HbA1c level and magnitude of HbA1c reduction with subsequent risk of cardiovascular events or death in patients with type 2 diabetes who initiate metformin. RESEARCH DESIGN AND METHODS: This was a population-based cohort study including all metformin initiators with HbA1c tests in Northern Denmark, 2000-2012. Six months after metformin initiation, we classified patients by HbA1c achieved (<6.5% or higher) and by magnitude of HbA1c change from the pretreatment baseline...
April 12, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28404658/association-of-glycemic-variability-in-type-1-diabetes-with-progression-of-microvascular-outcomes-in-the-diabetes-control-and-complications-trial
#10
John M Lachin, Ionut Bebu, Richard M Bergenstal, Rodica Pop-Busui, F John Service, Bernard Zinman, David M Nathan
OBJECTIVE: The Diabetes Control and Complications Trial (DCCT) demonstrated the beneficial effects of intensive versus conventional therapy on the development and progression of microvascular complications of type 1 diabetes. These beneficial effects were almost completely explained by the difference between groups in the levels of HbA1c, which in turn were associated with the risk of these complications. We assessed the association of glucose variability within and between quarterly 7-point glucose profiles with the development and progression of retinopathy, nephropathy, and cardiovascular autonomic neuropathy during the DCCT...
April 12, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28404657/predicting-and-reducing-driving-mishaps-among-drivers-with-type-1-diabetes
#11
Daniel J Cox, Linda A Gonder-Frederick, Harsimran Singh, Karen S Ingersoll, Tom Banton, Jesse H Grabman, Karen Schmidt, William Clarke
OBJECTIVE: Two aims of this study were to develop and validate 1) a metric to identify drivers with type 1 diabetes at high risk of future driving mishaps and 2) an online intervention to reduce mishaps among high-risk drivers. RESEARCH DESIGN AND METHODS: To achieve aim A, in study 1, 371 drivers with type 1 diabetes from three U.S. regions completed a series of established questionnaires about diabetes and driving. They recorded their driving mishaps over the next 12 months...
April 12, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28400430/bmi-and-all-cause-mortality-in-normoglycemia-impaired-fasting-glucose-newly-diagnosed-diabetes-and-prevalent-diabetes-a-cohort-study
#12
Eun Young Lee, Yong-Ho Lee, Sang-Wook Yi, Soon-Ae Shin, Jee-Jeon Yi
OBJECTIVE: This study examined associations between BMI and mortality in individuals with normoglycemia, impaired fasting glucose (IFG), newly diagnosed diabetes, and prevalent diabetes and identified BMI ranges associated with the lowest mortality in each group. RESEARCH DESIGN AND METHODS: A total of 12,815,006 adults were prospectively monitored until 2013. Diabetes status was defined as follows: normoglycemia (fasting glucose <100 mg/dL), IFG (100-125 mg/dL), newly-diagnosed (≥126 mg/dL), and prevalent diabetes (self-reported)...
April 11, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28396362/insulin-induced-distant-site-lipoatrophy
#13
LETTER
Aki Kondo, Akinobu Nakamura, Jun Takeuchi, Hideaki Miyoshi, Tatsuya Atsumi
No abstract text is available yet for this article.
April 10, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28389582/the-impact-of-continuous-glucose-monitoring-on-markers-of-quality-of-life-in-adults-with-type-1-diabetes-further-findings-from-the-diamond-randomized-clinical-trial
#14
William H Polonsky, Danielle Hessler, Katrina J Ruedy, Roy W Beck
OBJECTIVE: Continuous glucose monitoring (CGM) improves glycemic control, but data are inconclusive about its influence on quality of life (QOL). We investigated the impact of 24 weeks of CGM use on QOL in adults with type 1 diabetes (T1D) who use multiple daily insulin injections. RESEARCH DESIGN AND METHODS: DIAMOND was a prospective randomized trial that assessed CGM versus self-monitoring of blood glucose (SMBG) only in 158 adults with poorly controlled T1D...
April 7, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28385685/improvement-of-glucose-control-and-reduction-of-hypoglycemia-following-intravenous-immune-globulins-in-a-child-with-type-1-diabetes-and-high-levels-of-insulin-antibodies
#15
LETTER
Lucien Marchand, Perrine Luigi, Jerome Place, Fabienne Dalla-Vale, Anne Farret, Eric Renard
No abstract text is available yet for this article.
April 6, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28381479/insulin-resistance-predicts-cognitive-decline-an-11-year-follow-up-of-a-nationally-representative-adult-population-sample
#16
Laura L Ekblad, Juha O Rinne, Pauli Puukka, Hanna Laine, Satu Ahtiluoto, Raimo Sulkava, Matti Viitanen, Antti Jula
OBJECTIVE: The aim of this study was to examine whether insulin resistance, assessed by HOMA of insulin resistance (HOMA-IR), is an independent predictor of cognitive decline. RESEARCH DESIGN AND METHODS: The roles of HOMA-IR, fasting insulin and glucose, HbA1c, and hs-CRP as predictors of cognitive performance and its change were evaluated in the Finnish nationwide, population-based Health 2000 Health Examination Survey and its 11-year follow-up, the Health 2011 study (n = 3,695, mean age at baseline 49...
April 5, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28373205/metformin-use-in-prediabetes-among-u-s-adults-2005-2012
#17
Eva Tseng, Hsin-Chieh Yeh, Nisa M Maruthur
OBJECTIVE: To determine the prevalence of and characteristics associated with metformin use among U.S. adults with prediabetes using the National Health and Nutrition Examination Survey (NHANES) 2005-2012. RESEARCH DESIGN AND METHODS: The American Diabetes Association's guidelines for metformin use in prediabetes have evolved, with 2017 recommendations suggesting metformin be considered in patients with prediabetes and additional risk factors (BMI ≥35 kg/m(2), age <60 years, or prior gestational diabetes mellitus) or rising hemoglobin A1c (HbA1c)...
April 3, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28356319/fast-acting-insulin-aspart-improves-glycemic-control-in-basal-bolus-treatment-for-type-1-diabetes-results-of-a-26-week-multicenter-active-controlled-treat-to-target-randomized-parallel-group-trial-onset-1
#18
David Russell-Jones, Bruce W Bode, Christophe De Block, Edward Franek, Simon R Heller, Chantal Mathieu, Athena Philis-Tsimikas, Ludger Rose, Vincent C Woo, Anne Birk Østerskov, Tina Graungaard, Richard M Bergenstal
OBJECTIVE: This multicenter, treat-to-target, phase 3 trial evaluated the efficacy and safety of fast-acting insulin aspart (faster aspart) versus conventional insulin aspart (IAsp) in adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: The primary end point was change from baseline in HbA1c after 26 weeks. After an 8-week run-in, subjects were randomized (1:1:1) to double-blind mealtime faster aspart (n = 381), IAsp (n = 380), or open-label postmeal faster aspart (n = 382)-each with insulin detemir...
March 29, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28351898/sodium-glucose-cotransporter-2-inhibitors-and-diabetic-ketoacidosis-a-case-series-from-three-academic-institutions
#19
LETTER
Negin Misaghian-Xanthos, Afreen I Shariff, Kavya Mekala, Loretta R Fearrington, Tracy L Setji, Joseph A Aloi, John B Buse
No abstract text is available yet for this article.
March 28, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28351897/prevention-of-hypoglycemia-with-predictive-low-glucose-insulin-suspension-in-children-with-type-1-diabetes-a-randomized-controlled-trial
#20
Tadej Battelino, Revital Nimri, Klemen Dovc, Moshe Phillip, Natasa Bratina
OBJECTIVE: To investigate whether predictive low-glucose management (PLGM) of the MiniMed 640G system significantly reduces the rate of hypoglycemia compared with sensor-augmented insulin pump in children with type 1 diabetes. RESEARCH DESIGN AND METHODS: This randomized, two-arm, parallel, controlled, two-center open-label study included 100 children and adolescents with type 1 diabetes and glycated hemoglobin A1c ≤10% (≤ 86 mmol/mol) and using continuous subcutaneous insulin infusion...
March 28, 2017: Diabetes Care
journal
journal
20095
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"